US President Donald Trump on Thursday (April 2nd) signed an executive order imposing sweeping new tariffs on imported brand-name drugs, marking a major escalation in his administration’s push to lower drug prices and boost domestic manufacturing.
Under the order, a 100% tariff will be applied to brand-name drug imports unless manufacturers agree to government-backed pricing arrangements or move production to the United States. The policy targets high-cost proprietary drugs that are manufactured overseas and sold at significantly higher prices in the US compared to other developed markets.
Deadlines for fulfillment
The administration has given drug companies limited room to comply. Big drugmakers have 120 days to outline plans to avoid the tariffs, while smaller firms have 180 days.
Companies that commit to moving production to the US will be eligible for a reduced tariff rate of 20%, providing a transition path for companies that adjust their operations.
Incentives through price agreements
Drugmakers can avoid tariffs entirely, both by onshoring production and by entering into “most favored nation” pricing agreements with the US Department of Health and Human Services. These agreements aim to bring drug prices in the US more in line with those in other developed countries.
The government has so far reached agreements with 17 pharmaceutical companies, with 13 finalized and four still under negotiation, Reuters reported.
Big companies are already on board
Some of the world’s largest drug manufacturers have already signed the initiative, Reuters reports. The deals exempt participating companies from tariffs for three years, offering temporary relief until broader reforms take effect.
Pressure on smaller drug makers
Industry sources indicate, the reporter said, that small and medium-sized pharmaceutical companies are actively seeking individual arrangements with the government to avoid both the tariffs and the new pricing requirements.
Generics exempt from tariffs
The administration clarified that generic drugs will remain exempt from the new tariffs. This is a significant concession because generics make up more than 90% of drugs sold in the United States, according to federal data.
Addressing high drug prices
The policy comes amid long-standing concerns about the high cost of prescription drugs in the US, where patients often pay nearly three times more than patients in other developed countries.
